Game Of Thrones: Bayer Looks To Lead China’s OTC Market
This article was originally published in The Tan Sheet
Executive Summary
The recent acquisition of Dihon Pharmaceutical Group marks progress toward Bayer’s goal of becoming the leader in the OTC sector in China. Dihon provides an entry into the TCM arena, which makes up about half of the OTC segment in China, the firm says.
You may also be interested in...
Dihon Acquisition Doubles Bayer’s Consumer Health Presence In China
Bayer acquired its second Chinese consumer health care firm to gain market share amid the country’s OTC consolidation trend. Dihon specializes in antifungal creams and herbal drugs for women’s and traditional Chinese medicines.
China OTC Drug Sales Pummeled By Pseudoephedrine Restrictions
Multinational cold and cough OTC products have suffered a serious setback in China, as government restricts usage of drugs containing pseudoephedrine.
Sanofi Acquires BMP Sunstone To Expand Chinese Consumer Health Portfolio
Sanofi-Aventis gains a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys.